Skip to main navigation Skip to search Skip to main content

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

  • I. Vaxman
  • , S. K. Kumar
  • , F. Buadi
  • , M. Q. Lacy
  • , D. Dingli
  • , S. Hayman
  • , T. Kourelis
  • , R. Warsame
  • , Y. Hwa
  • , A. Fonder
  • , M. Hobbs
  • , E. Muchtar
  • , N. Leung
  • , P. Kapoor
  • , R. Go
  • , Y. Lin
  • , W. Gonsalves
  • , M. Siddiqui
  • , R. A. Kyle
  • , S. V. Rajkumar
  • M. A. Gertz, A. Dispenzieri*
*Corresponding author for this work
  • Mayo Clinic Rochester, MN
  • Rabin Medical Center Israel

Research output: Contribution to journalLetterpeer-review

16 Scopus citations
Original languageEnglish
Article number91
JournalBlood Cancer Journal
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

Funding

Funders
Predolin Foundation
National Cancer Institute
Jabbs Foundation

    Cite this